ôßÄÏ´óѧãÆɼ°Í¿Öø³ØÅäºÏͨѶÔÚSignal Transduction and Targeted TherapyÔÚÏß½ÒÏþÌâΪ¡°Generation of inactivated IL2RG and RAG1 monkeys with severe combined immunodeficiency using base editing¡±µÄÑо¿ÂÛÎÄ£¬¸ÃÑо¿Ìá³öÁËÒ»ÖÖʹÓÃCBE4maxϵͳʹIL2RGºÍRAG1»ùÒòʧ»îÀ´¹¹½¨ÃâÒßȱÏݺïÄ£×ÓµÄÒªÁì¡£¾Óɼî»ù±à¼µÄºï×ÓÌåÏÖ³öÑÏÖØÊÜËðµÄÃâÒßϵͳ£¬ÆäÌØÕ÷ÊÇÁÜ°Íϸ°ûïÔÌ¡¢ÁÜ°ÍÑùÆ÷¹ÙήËõºÍ³ÉÊìTϸ°ûȱ·¦¡£±ðµÄ£¬ÕâЩ¾ÓÉ»ùÒò±à¼µÄºï×ÓÄܹ»³ÐÔغÍÖ§³ÖÈËÀàÈéÏÙ°©Ï¸°ûµÄÉú³¤£¬´Ó¶øµ¼ÖÂÖ×ÁöµÄÐγɡ£×ÜÖ®£¬¸ÃÑо¿ÒѾÀֳɿª·¢ÁËÒ»ÖÖÃâÒßȱÏݺïÄ£×Ó£¬¸ÃÄ£×Ó¾ßÓÐʹÓÃCBE4maxϵͳÔö½øÖ×ÁöÉú³¤µÄÄÜÁ¦¡£ÕâЩÃâÒßȱÏݺï×ÓÏÔʾ³ö×÷ΪÍƽøÉúÎïҽѧºÍת»¯Ñо¿µÄÃû¹ó¹¤¾ßµÄÖØ´óDZÁ¦¡£
ÑÏÖØÍŽáÃâÒßȱÏÝ(SCIDs)°üÀ¨Ò»×éÒÅ´«ÐÔ¼²²¡£¬ÑÏÖØÆÆËðÃâÒßϵͳµÄ¹¦Ð§¡£Õâµ¼ÖÂÀ´×ÔÐØÏٺ͹ÇËèµÄTϸ°ûºÍBϸ°ûµÄȱʧ»òïÔÌ£¬µ¼ÖÂϸ°ûºÍÌåҺ˳ӦÐÔÃâÒßÊÜËð¡£SCIDµÄ·¢²¡»úÖÆÖ÷ÒªÉæ¼°ÓÉÓÚàÑßÊ´úлȱÏÝ¡¢Í¨¹ý³£¼û¦ÃÁ´ÒÀÀµÐÔϸ°ûÒò×ÓÊÜÌåµÄÐźŴ«µ¼Òì³£¡¢V(D) JÖØ×éÒì³£ÒÔ¼°Ç°TCR/TCRÐźŴ«µ¼È±Ïݵ¼ÖµÄÇ°ÌåÁÜ°Íϸ°û¹ýÔçéæÃüһЩ»ùÒòÍ»±äÒѱ»È·¶¨ÎªSCIDsµÄÓÕÒò£¬°üÀ¨MALT1¡¢ZAP70¡¢IL21R¡¢FOXN1¡¢CORO1A¡¢RAG1/2¡¢IL2RG¡¢AK2¡¢IKBK2¡¢UNC119¡¢LCK¡¢TTC7A¡¢CARD11ºÍBCL10¡£ÆäÖУ¬IL2RG£¬Ò²±»³ÆΪ¹«¹²¦ÃÁ´£¬×÷ΪIL-21¡¢IL-15¡¢IL-9¡¢IL-4ºÍIL-7ÊÜÌå¹²ÓеÄIL-2ÊÜÌåµÄÑÇ»ù¡£
IL2RGÍ»±äµ¼ÖÂXÁ¬ËøÑÏÖØÍŽáÃâÒßȱÏÝ(X-SCID)£¬ÕâÊÇ×î³£¼ûµÄSCIDÐÎʽ£¬Õ¼ËùÓв¡ÀýµÄ50%¡£ÔÚX-SCIDÖУ¬TºÍNKϸ°ûȱʧ»òÏÔ×ÅïÔÌ£¬¶øBϸ°ûÌåÏÖ³ö¹¦Ð§ÕÏ°£¬ÆäÊýÄ¿Õý³£»òÔöÌí¡£ÁíÒ»¸öÓëSCIDÏà¹ØµÄ»ùÒòÊÇRAG1£¬Ëüͨ¹ýÔö½ø·¢ÓýÖеÄÁÜ°Íϸ°ûV(D)JÖØ×éÔÚ˳ӦÐÔÃâÒßÖÐÆðÒªº¦×÷ÓÃRAGÖØ×éø(RAG1/2)½«¿É±ä(V)¡¢¶àÑùÐÔ(D)ºÍÅþÁ¬(J)»ùÒòƬ¶ÏËæ»ú×éºÏ£¬ÌìÉúV(D)JÍâÏÔ×Ó£¬±àÂëTϸ°ûÊÜÌåºÍ¿¹ÌåµÄ¿É±äÇø¡£Ðí¶àËðʧ¹¦Ð§µÄRAG1Í»±äÌåÒѱ»È·¶¨ÎªÈËÀàSCIDµÄÖ²¡ÒòËØ¡£ÕâЩͻ±äÌåµÄÌØÕ÷ÊDz¿·ÖÂÑ°×±í´ïºÍTϸ°ûºÍBϸ°ûµÄÓÐÏÞ±¬·¢£¬Í¬Ê±¼á³ÖÕý³£NKϸ°ûµÄ¹¦Ð§¡£
ÃâÒßϵͳÊÜËðµÄ¶¯Îï¿É·ÖΪÏÈÌìÐÔÍ»±äÒýÆðµÄÒÅ´«ÃâÒßȱÏÝ»òͨ¹ýÉúÎïÊÖÒÕÒªÁìÈ˹¤ÓÕµ¼µÄÒÅ´«ÃâÒßȱÏÝ¡£ÏÖÔÚ£¬Óм¸ÖÖÀàÐ͵ÄÒÅ´«ÃâÒßȱÏݶ¯ÎïÄ£×Ó£¬ÈçСÊó¡¢´óÊóºÍÖí¡£ÕâЩÃâÒßȱÏݶ¯ÎïÔÚÖ×Áöѧ¡¢¸Éϸ°ûÖÎÁÆ¡¢ÃâÒßϵͳÑо¿ºÍѬȾ²¡µÈÁìÓòÓÐÆÕ±éµÄÓ¦Óá£ÈËÔ´»¯Ð¡¶¯ÎïÄ£×ÓÔÚÃâÒßÖ×ÁöѧÑо¿ÖÐÌØÊâÓмÛÖµ£¬ÓÉÓÚËüÃÇÌṩÁËÁÙ´²×ª»¯µÄDZÁ¦¡£È»¶ø£¬Õë¶ÔÏêϸÇéÐÎ׼ȷѡÔñºÏÊʵÄÄ£×ÓÈÔÈ»¾ßÓÐÌôÕ½ÐÔ¡£ÏÖÔÚ»¹²»¿ÉÄÜÕÒµ½Ò»ÖÖÍêÈ«¸´ÖÆÈËÀàÉúÎïѧËùÓз½ÃæµÄСÊóÄ£×Ó£¬²¢ÇÒһЩSCIDСÊóËæ×ÅÄêËêµÄÔöÌí»á·ºÆð¡°ÃâÒß×ß©¡±¡£ÕâЩ¡°×ß©¡±µ¼ÖÂСÊ󱬷¢ÉÙÁ¿¹¦Ð§ÐÔTϸ°ûºÍBϸ°û£¬ÒÔ¼°ÃâÒßÇòÂѰס£SCIDСÊóÃâÒß×ß©±³ºóµÄ·Ö×Ó»úÖÆÉв»ÇåÎú£¬ÏÖÔÚ»¹Ã»ÓÐÈ·¶¨µÄÕï¶Ï±ê×¼¡£·ÇÈËÁ鳤ÀදÎï(NHPs)ÔÚϵͳ·¢ÓýÉÏÓëÈËÀà¸ß¶ÈÏà¹Ø£¬ÔÚÐÄÀíÉÏÓÐÐí¶àÏàËÆÖ®´¦£¬°üÀ¨ÃâÒßϵͳÌØÕ÷NHPsÓëÈËÀàÔÚÒÅ´«ºÍÐÄÀíÉϵÄÏàËÆÖ®´¦Ê¹ËüÃdzÉΪÉúÎïҽѧÑо¿µÄÓÅÒìÄ£×Ó¡£Òò´Ë£¬½¨ÉèÃâÒßȱÏݺïÄ£×ÓÊÆÔÚ±ØÐС£
¼î»ù±à¼ºïµÄÌìÉúÀú³ÌʾÒâͼ£¨Í¼Ô´×ÔSignal Transduction and Targeted Therapy£©
ËäÈ»CRISPR/Cas9ÓÐÍûÓÃÓÚÖÎÁƺÍÉúÎïѧÑо¿£¬µ«ÓÉÓÚËüÒÀÀµDNAË«Á´¶ÏÁÑ(DSBs)À´Ôö½ø»ùÒò±à¼£¬Òò´ËÒýÆðÁËÈËÃǵĵ£ÐÄ¡£CRISPR/Cas9ÓÕµ¼µÄDSBs¿Éµ¼ÖÂÊýǧ¸ö¼î»ù¶ÔµÄȱʧ£¬´Ó¶øµ¼Ö¿ÉÄܶÔÓÐË¿ÆÆËé»îÐÔϸ°û±¬·¢Óк¦Ó°ÏìµÄ»ùÒòÐ͵ı¬·¢¡£ÀýÈ磬µ±Ó¦ÓÃÓÚÈËÀà¶àÐÑĿϸ°ûʱ£¬CRISPR/Cas9¿ÉÒÔÓÕµ¼p53Í»±ä£¬ÏÞÖÆÁËϸ°ûÌæ»»ÁÆ·¨µÄ¿ÉÐÐÐÔ¡£±ðµÄ£¬»ùÒò±à¼µÄЧÂÊÊܵ½²åÈëȱʧͻ±äµÄ¸ßƵÂʵÄ×è°£¬ÔÚHEK293Tϸ°ûÖУ¬CRISPR½éµ¼µÄͬԴ¶¨ÏòÐÞ¸´ÂʽöµÖ´ï38%¡£
È»¶ø£¬´ó´ó¶¼ÒÑÖªµÄÒÅ´«¼²²¡Ö÷ÒªÊÇÓɵ¥ºËÜÕËá¶à̬ÐÔ(SNPs)ÒýÆðµÄ¡£Òò´Ë£¬ÐèÒªÄܹ»ÔÚ²»ÒýÈëDSBsµÄÇéÐÎÏÂÌØÒìÐÔµØÐÞ¸ÄÄ¿µÄλµãÉϵĵ¥¸ö¼î»ù¶ÔµÄÒªÁì¡£¼î»ù±à¼Æ÷ÌṩÁ˿ɱà³ÌÐÔºÍÎÞаÐÔ£¬Ïû³ýÁ˶ÔDSBsµÄÐèÇó£¬Õ½Ê¤Á˹ŰåCas9ºËËáøÔÚ»ùÒò±à¼ÖеľÖÏÞÐÔ¡£°ûà×़î»ù±à¼Æ÷(CBEs)¾ßÓаûà×à¤ÍÑ°±Ã¸»îÐÔ£¬Òѱ»ÓÐÓõØÓÃÓÚÔÚ°üÀ¨ÈËÀࡢСÊóºÍ×÷ÎïÔÚÄÚµÄÖÖÖÖÉúÎïÌåµÄ»ùÒò×éÖÐÒýÈë׼ȷµÄµ¥¼î»ùÍ»±ä¡£ÓëCBE4Ïà±È£¬CBE4maxϵͳÊÇC-Gµ½T-Aת»¯µÄÔöÇ¿¹¤¾ß£¬ÒÑÔÚСÊóÄ£×ÓÖпª·¢ºÍÑéÖ¤£¬Ëæºó¶Ô²¸È鶯ÎïÎïÖÖ¾ÙÐÐÁËÓÅ»¯¡£
¸ÃÑо¿Ê¹ÓÃCBE4maxϵͳÔÚIL2RGºÍRAG1»ùÒòÖÐÒýÈëÌØÒìÐÔµ¥ºËÜÕËáÌæ»»£¬ÀÖ³ÉʵÏÖÁË·ÇÈËÁ鳤ÀදÎïÃâÒßȱÏÝÄ£×ÓµÄÌìÉú¡£¼î»ù±à¼Àú³Ìµ¼Ö±»±à¼ºï×ÓµÄÃâÒßϵͳÏÔ×ÅÊÜËð£¬ÌåÏÖΪÁÜ°Íϸ°ûïÔÌ¡¢ÁÜ°ÍÑùÆ÷¹ÙήËõºÍȱ·¦³ÉÊìTϸ°û¡£±ðµÄ£¬Ñо¿Ö°Ô±ÊӲ쵽ÈËÀàÈéÏÙ°©Ï¸°ûÔÚ¼î»ù±à¼µÄºï×ÓÌåÄÚ´æ»îºÍÔöÖ³µÄÏÔÖøÄÜÁ¦¡£ÕâЩÓÐÃâÒßȱÏݵĺï×ÓÊÇÁÙ´²Ç°Ñо¿µÄÃû¹ó¹¤¾ß£¬²¢ÃÖºÏÁËС¶¯ÎïÄ£×ÓÓëÈËÀàÖ®¼äµÄ²î±ð¡£ËüÃǵÄʹÓÿÉÒÔÏÔÖøÌá¸ßÁÙ´²Ç°Ñо¿µÄÓÐÓÃÐÔ£¬Îª¿¹°©Ò©ÎïµÄ¿ª·¢ºÍÔÙÉúҽѧÁìÓòµÄÒìԴϸ°û»òÆ÷¹ÙÒÆÖ²ÌṩÒÀ¾Ý¡£